1,085 results match your criteria: "Recurrent Respiratory Papillomatosis"
"A systematic literature review of the epidemiology, clinical, economic and humanistic burden in recurrent respiratory papillomatosis".
Respir Res
December 2024
MSD, Puteaux, France.
Introduction: Recurrent respiratory papillomatosis (RRP) is a chronic disease caused by human papillomavirus (HPV), characterized by recurrent papillomas in the respiratory tract. Presenting as either juvenile-onset RRP (JoRRP) or adult-onset RRP (AoRRP), the severity of the disease is subjective and unpredictable. Lack of curative therapies necessitates disease management involving repeated surgical removal of lesions.
View Article and Find Full Text PDFTrends in the incidence and prevalence of juvenile-onset recurrent respiratory papillomatosis following implementation of national HPV vaccination initiatives: a systematic review.
Acta Otolaryngol
November 2024
Department of Otorhinolaryngology, Head and Neck Surgery, and Audiology, Rigshospitalet, Copenhagen, Capital Region, Denmark.
Article Synopsis
- Infection with low-risk HPV types 6 and 11 can cause recurrent respiratory papillomatosis (JoRRP) in children, which leads to benign growths in the larynx.
- A systematic review studied the effects of national HPV vaccination programs on the incidence and prevalence of JoRRP, analyzing data from four studies that included 622 patients from countries like Australia, New Zealand, and the U.S.
- Results showed a significant decline in JoRRP cases after vaccination, with higher vaccination rates linking to lower disease burden, highlighting the importance of widespread HPV vaccination for future health outcomes.
Nationwide Survey on Incidence and Management of Recurrent Respiratory Papillomatosis in Japan.
Laryngoscope
November 2024
The Japan Broncho-esophagological Society, Tokyo, Japan.
Objectives: To investigate the incidence, laryngeal distribution, management, and postoperative clinical course of patients with newly diagnosed adult-onset recurrent respiratory papillomatosis (RRP) in Japan.
Methods: An initial brief questionnaire was sent to 782 institutions, including all 101 core and 627 collaborating institutions providing board certification programs accredited by the Japanese Society of Otorhinolaryngology-Head and Neck Surgery. A detailed questionnaire regarding patient age, sex, Derkay's score, surgery, and postoperative clinical course was sent to 196 institutions caring for patients with either newly or previously diagnosed RRP.
Prevalence and risk factors for dysplasia and malignancy in a large cohort of patients with recurrent respiratory papillomatosis.
J Laryngol Otol
November 2024
ENT Department, Liverpool Head and Neck Centre, Liverpool University Hospital Foundation Trust, Lower Lane, Liverpool, UK.
Long-Term Infection With a Particular Human Papillomavirus (HPV) Genotype, HPV Subtype, or HPV Genomic Variant Does not Significantly Influence the Clinical Course of Recurrent Respiratory Papillomatosis.
J Med Virol
November 2024
Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Recurrent respiratory papillomatosis (RRP) is caused by human papillomaviruses (HPV) 6 and 11, but the role of their genomic variants in the disease's clinical course is unclear. This study investigated whether long-term persistence of a particular HPV genotype, subtype or genomic variant influences the RRP clinical course. HPV genotyping was performed in paired baseline and follow-up RRP laryngeal tissue specimens of 59 patients.
View Article and Find Full Text PDFRecurrent respiratory papillomatosis: Immunological mechanisms involved in recurrence.
Int Rev Immunol
November 2024
Centro Medico Nacional "20 de Noviembre" Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Ciudad de México, México.
Article Synopsis
- - Recurrent respiratory papillomatosis is a non-cancerous condition affecting various age groups that leads to symptoms like difficulty speaking and hoarseness, greatly impacting quality of life.
- - The disease can vary in severity, with some cases resolving on their own, while others may lead to serious airway blockages requiring frequent surgeries.
- - The review focuses on understanding the immune-related mechanisms behind the recurrence of this condition and looks at how these factors relate to treatment and risks involved.
Genomic diversity of HPV6 and HPV11 in recurrent respiratory papillomatosis: Association with malignant transformation in the lungs and clinical outcomes.
Tumour Virus Res
December 2024
Laboratory MIVEGEC (Univ Montpellier, CNRS, IRD), French National Center for Scientific Research (CNRS), Montpellier, France. Electronic address:
Recurrent respiratory papillomatosis (RRP) is a rare, proliferative disease caused by human papillomavirus 6 (HPV6) and HPV11. RRP can occasionally spread and undergo malignant transformation. We analysed samples across time for five RRP patients with malignant transformation and four with highly recurrent, non-malignant RRP by applying high-throughput sequencing.
View Article and Find Full Text PDF[Update on HPV-associated head and neck cancers-highlights of the 2024 ASCO Annual Meeting].
HNO
December 2024
Kopf-Hals-Tumorzentrum des Comprehensive Cancer Center Ulm, Klinik für Hals-Nasen-Ohrenheilkunde und Kopf-Hals-Chirurgie, Universitätsklinik Ulm, Ulm, Deutschland.
Background: Human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) is becoming increasingly important in head and neck oncology. At this year's conference of the American Society of Clinical Oncology (ASCO), a large number of papers were presented on the topic of HPV-associated HNSCC, particularly with regard to neoadjuvant treatment approaches, radiation de-escalation strategies, therapeutic vaccines, and treatment monitoring. In this context, study results on the treatment of HPV-related recurrent respiratory papillomatosis (RRP) were also presented.
View Article and Find Full Text PDFCurrent Practice, Safety and Efficacy of Interventions for Recurrent Respiratory Papillomatosis: Evidence From a UK Registry.
Clin Otolaryngol
October 2024
The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Article Synopsis
- - The study aimed to evaluate the safety and effectiveness of treatments for recurrent respiratory papillomatosis (RRP) in UK NHS hospitals, involving data collection from patients between April 2018 and August 2022, along with some retrospective data from earlier years.
- - A total of 304 patients (including 65 children) were analyzed; findings showed that children had a more severe form of RRP compared to adults, with microdebrider surgeries being the most common treatment.
- - The research concluded that RRP is more aggressive in children, treatment varies by age, and overall management was safe, with few complications and effective results; it highlighted the need for standardized reporting to better track disease progression and safety. *
Effective control of a severely progressive recurrent respiratory papillomatosis with repetitive cryotherapy.
Korean J Intern Med
November 2024
Department of Internal Medicine, Jeonbuk National University Medical School, Jeonju, Korea.
Recurrent Respiratory Papillomatosis in the Post-Human Papillomavirus Vaccination Era.
JAMA Pediatr
December 2024
Department of Otolaryngology, University of California San Diego School of Medicine, Division of Pediatric Otolaryngology, Rady Children's Hospital, San Diego.
Adjuvant treatments for recurrent respiratory papillomatosis: a descriptive review and proposed management guideline in adults.
J Laryngol Otol
October 2024
National Centre for Airway Reconstruction, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom.
Evaluating the efficacy and safety of intralesional bevacizumab in the treatment of recurrent respiratory papillomatosis: A systematic review.
Int J Pediatr Otorhinolaryngol
November 2024
Peninsula Medial School, University of Plymouth, Plymouth, UK; University Hospitals Plymouth NHS Trust, Ear Nose and Throat Department, Plymouth, UK. Electronic address:
Article Synopsis
Advances in Recurrent Respiratory Papillomatosis Treatment: Adjuvant Intralesional Bevacizumab's Impact, Potential and Insights from a Case Series Study.
Indian J Otolaryngol Head Neck Surg
October 2024
Department of Otorhinolaryngology, Government ENT Hospital, Osmania Medical College, Door No.5-1-174, Opposite State Bank of India Head Office, Bank Street Road Koti, Hyderabad, 500095 India.
Article Synopsis
- Recurrent respiratory papillomatosis is a benign but aggressive condition caused mainly by HPV types 6 and 11, leading to the formation of warts in the respiratory tract, particularly the larynx, necessitating multiple surgeries for management.
- A study conducted on 13 patients aged 3 to 30 evaluated the effects of intralesional bevacizumab as an adjuvant therapy, which involved three injections over 12 weeks.
- The results indicated that this treatment significantly extended the time between surgeries and reduced the total number of procedures needed each year, with no reported adverse effects, showing improvements in patient health as measured by the Derkay score.
Successful Bevacizumab Therapy in a 25-Year-Old Patient with Recurrent Respiratory Papillomatosis.
Eur J Case Rep Intern Med
September 2024
Riga Stradins University, Riga, Latvia.
Article Synopsis
- Recurrent respiratory papillomatosis (RRP) is a long-term illness caused by HPV that leads to growths in the breathing area, often requiring many surgeries.
- A 25-year-old woman with RRP had many treatments over the years, but they didn't fully help her, until she tried a new medicine called bevacizumab in 2023, which reduced her need for surgery.
- This case shows that bevacizumab could be a good option for treating RRP, but more research is needed to ensure it's safe and effective long-term.
Cost-Effectiveness of 9-Valent HPV Vaccination for Patients Treated for High-Grade Cervical Intraepithelial Neoplasia in the UK.
JAMA Netw Open
October 2024
Merck & Co Inc, Rahway, New Jersey.
Article Synopsis
- Patients treated for severe cervical cell changes (CIN grade ≥2) have a higher chance of getting more CIN or HPV-related diseases, and vaccination can help reduce this risk.
- The study looked at whether giving an HPV vaccine before surgery, along with regular check-ups, is worth it compared to just the check-ups alone in the UK.
- They used models to understand the health outcomes and costs involved, and their goal was to see how effective and cost-friendly the vaccination would be in preventing serious diseases like cervical cancer.
[Recurrent respiratory papillomatosis].
Rev Med Suisse
October 2024
Service d'ORL et de chirurgie cervicofaciale, Centre hospitalier universitaire vaudois, 1011 Lausanne.
Recurrent respiratory papillomatosis is a chronic infection of the airway mucosa by the human papilloma virus, in the form of recurrent exophytic papilloma. Two clinical forms are distinguished: juvenile and adult onset. Depending on their size and location, papilloma can cause dysphonia, pharyngeal discomfort, until obstruction of the airway.
View Article and Find Full Text PDFRecurrent respiratory papillomatosis: comparing in-office and operating room treatments.
Acta Otorhinolaryngol Ital
August 2024
Head and Neck Department, IRCCS Policlinico San Martino, Genoa, Italy.
Article Synopsis
- The study focuses on a new way to treat a disease called recurrent respiratory papillomatosis (RRP) using both office visits and general anesthesia.
- They compared how well patients felt after treatment between those using the new method and those who only had general anesthesia before.
- Results showed that patients treated in the office had a better quality of life and fewer healthcare costs after a year of treatment.
Characterization of HPV6/11-reactive T-cell subsets in papillomas of patients with juvenile-onset recurrent respiratory papillomatosis and identification of HPV11 E7-specific candidate TCR clonotypes.
J Virol
October 2024
Laboratory of Tumor Immunology, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Article Synopsis
- Juvenile-onset recurrent respiratory papillomatosis (JORRP) is linked to low-risk HPV types 6 and 11, with CD8+ tissue-resident memory T cells playing a critical role in the immune response against this infection.
- Research revealed that CD8+ T cells producing interferon-gamma (IFN-γ) expanded in JORRP patients and their levels were inversely related to disease severity and surgical frequency.
- The study identified specific T cell receptor (TCR) clonotypes that could be targeted for potential TCR-engineered therapies, shedding light on the local immune dynamics in response to HPV6/11 infections.
Quantifying Bevacizumab Efficacy in Recurrent Respiratory Papillomatosis.
Laryngoscope
January 2025
School of Medicine, Southeast University, Nanjing, China.
Article Synopsis
- Scientists created a new way to check if a medicine called Bevacizumab (Bev) works well for treating a throat problem called Recurrent Respiratory Papillomatosis (RRP).
- In a study with 21 patients, they found that the medicine worked better after the first dose, and by the third dose, every patient showed improvement.
- Although some patients had side effects like high blood pressure, the treatment was mostly safe, and the new method they made to measure results could help in future studies.
Mucosal Injection of the Silicon Phthalocyanine Pc 4 in a Rabbit Model-A Pilot Study.
Laryngoscope
January 2025
Department of Otolaryngology-Head and Neck Surgery, University Hospitals Cleveland Medical Center, Cleveland, Ohio, U.S.A.
Article Synopsis
- Researchers tested a new medicine called Pc 4 to see if it can help treat certain throat problems by injecting it directly into mouth and throat tissue in rabbits.
- The rabbits had no major reactions or problems after getting the injections, which is a good sign.
- The study showed that injecting Pc 4 into the tissues seemed safe, with only slight signs of irritation that weren't serious.
Forecasting Disease Burden with a Dynamic Transmission Model of Human Papillomavirus and Recurrent Respiratory Papillomatosis in the United States.
Viruses
August 2024
Biostatistics and Research Decision Sciences (BARDS), Merck & Co., Inc., Rahway, NJ 07065, USA.
Article Synopsis
- Juvenile- and adult-onset recurrent respiratory papillomatosis (JORRP and AORRP) are rare and serious medical conditions caused by HPV, leading to growths in the throat and can even be deadly.
- The main treatment for these conditions is surgery, but getting vaccinated against HPV can help prevent infection.
- A new model shows that since the HPV vaccine was introduced in the US, it has saved many lives and reduced the number of cases significantly, with expected cases dropping to very low numbers by 2040.
[Step treatment of invasive recurrent respiratory papillomatosis in children: a case report].
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
August 2024
Department of Otolaryngology Head and Neck, BenQ Medical Center, the Affiliated BenQ Hospital of Nanjing Medical University, Nanjing 210019, China.
Results of CO2 laser surgery in laryngeal papillomatosis.
Oral Oncol
November 2024
Department of Otolaryngology, Laryngological Oncology and Maxillofacial Surgery, University Hospital No. 2, 85-168 Bydgoszcz, Poland; Department of Otolaryngology, Phoniatrics and Audiology, Collegium Medicum, Nicolaus Copernicus University, 85-168 Bydgoszcz, Poland. Electronic address:
Article Synopsis
- ecurrent respiratory papillomatosis is a condition caused by HPV that affects the throat and can cause growths.* *Doctors often treat these growths by using a special laser to remove them, but it's important to do thorough checks before surgery.* *In a study of 31 patients, many needed surgery multiple times, and some also received additional treatments to help stop the growths from coming back.*
Effectiveness of surgery combined with photodynamic therapy for recurrent respiratory papillomatosis.
Am J Otolaryngol
December 2024
School of Medicine, Southeast University, 87 Dingjiaqiao, Hunan Road, Nanjing 210009, Jiangsu, China; Department of Otolaryngology-Head and Neck Surgery, BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical University, 71 Hexi Street, Nanjing 210019, Jiangsu, China; Nanjing Medical Key Laboratory of Laryngopharynx-Head & Neck Oncology, 71 Hexi Street, Nanjing 210019, Jiangsu, China. Electronic address:
Objective: This study aims to analyze the safety and effectiveness of a new model of surgery combined with Photodynamic therapy for treating Recurrent Respiratory Papillomatosis (RRP).
Methods: Review the case data of patients with RRP who opted for comprehensive surgery combined with Photodynamic therapy at the Nanjing BenQ Medical Center, from January 2021 to May 2023. The efficacy of this program was evaluated by comparing the annual number of surgeries and Derkay scores before and after the surgery.